SHARP THERAPEUTICS
Investor Relations
TSXV: SHRX
A message from our CEO
Current treatments for genetic diseases—like biologics and gene therapies—are costly, slow to develop, and have significant risks. Our small molecule drug platform offers a faster, less costly and scalable solution that can disrupt these markets and deliver better outcomes for patients and payors. We’re excited about the future and invite you to join us in shaping the next generation of treatment.
Scott Sneddon, PhD, JD
Latest Presentation
Coming soon…
Events
Stock Information*
* All $ figures are in Canadian currency (CAD).
